公司概述
BrainsWay Ltd. (TICKER: BWAY) specializes in the development and commercialization of noninvasive neurostimulation therapies designed to address mental health disorders across the United States, East Asia, and international markets. The company operates within the Healthcare sector, specifically targeting the Medical Devices industry, which involves creating advanced technologies for diagnostic and therapeutic applications without invasive surgical procedures. As of the latest reported data, the company maintains a market capitalization of $572.47M and generates annual revenue of $52.23M, while its total employee count is listed as N/A. These valuation and revenue figures indicate that BrainsWay occupies a mid-cap position with significant revenue generation relative to its market size, reflecting the high-value nature of its specialized deep transcranial magnetic stimulation platform technology for treating major depressive disorders and related conditions.
财务健康
The company reported a trailing twelve-month revenue of $52.23M, net income of $7.63M, and EBITDA of $5.86M, revealing a cost structure where operating expenses and taxes consumed a substantial portion of the top line before reaching the bottom line. The business generated positive free cash flow of $814,250, which provides the financial flexibility to fund research and development initiatives or repay debt without relying on external financing. BrainsWay demonstrates strong profitability with a gross margin of 75.4%, indicating highly efficient production or high pricing power for its medical devices, an operating margin of 13.2% that reflects reasonable control over operating costs, and a profit margin of 14.6% that highlights effective tax management and cost structure. On the balance sheet, the company holds $67.70M in cash against $6.82M in debt, resulting in a debt-to-equity ratio of 9.31, which suggests a leveraged position where debt usage is significant relative to equity capitalization. Despite the leverage, the current ratio stands at 3.83, indicating robust short-term liquidity as current assets are nearly four times greater than current liabilities. Return on equity is recorded at 11.3% while return on assets sits at 2.6%, metrics that reveal management is generating returns for shareholders that are significantly higher than the return generated on the total asset base, likely due to the high equity multiplier inherent in the leverage structure.
估值评估
The stock currently trades at a trailing P/E ratio of 79.44 and a forward P/E of 32.01, implying that the market expects a substantial acceleration in earnings growth to justify the current multiple contraction. The price-to-book ratio is 7.16, suggesting the market prices the company at a significant premium over its net asset value, which is typical for technology firms with intangible assets and strong intellectual property moats. Alternative valuation metrics further illustrate this premium, with a price-to-sales ratio of 10.96 and an EV/EBITDA multiple of 79.06, indicating that investors are willing to pay a high multiple for every dollar of sales and earnings. The 52-week high is $14.69 and the 52-week low is $3.92, meaning the current share price sits within a wide trading range that reflects significant volatility over the past year. The beta value is listed as N/A, preventing a direct assessment of price volatility relative to the broader market index using standard statistical measures found in this dataset.
Growth & Income
Revenue growth year-over-year is 27.4% while earnings growth year-over-year is 390.8%, indicating that earnings are expanding at a rate far exceeding revenue growth, which often points to significant leverage effects or one-time cost savings impacting the bottom line. The company does not pay dividends, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, meaning that all net income is retained within the business to fuel further expansion and research rather than being distributed to shareholders. This reinvestment strategy aligns with the growth phase of a medical device company that prioritizes capital allocation toward developing new indications and technologies. Overall, BrainsWay presents a growth-oriented profile characterized by double-digit revenue expansion, triple-digit earnings acceleration, and a capital structure that prioritizes internal funding over shareholder payouts.